

## **Prescribing Information**

### **PrVPI-BENZTROPINE**

#### **Benztropine Mesylate Injection, USP 1 mg/ml**

Antiparkinsonian Agent  
Intramuscular / Intravenous

### **ACTION AND CLINICAL PHARMACOLOGY**

VPI-Benzotropine is a synthetic compound resulting from the combination of the active portions of atropine and diphenhydramine. Benztropine possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism.

Benztropine antagonizes the effect of acetylcholine. This decreases the imbalance between the neurotransmitters acetylcholine and dopamine, which may improve the symptoms of early Parkinson's disease.

In a clinical study measuring serum levels of neuroleptics and anticholinergics via radioreceptor assay, the correlation between total daily dose of benztropine and serum concentration was extremely poor ( $r=0.281$ ). Serum concentrations varied nearly 100-fold with given doses between 2 and 6 mg/day. A markedly non-linear relationship between daily dose and serum anticholinergic drug levels was observed with an increasing oral dosage of benztropine. In most cases, 2 mg increments in oral dose were associated with several-fold increases in the serum level of anticholinergic activity.

It has been reported that the duration of action for benztropine may persist for up to 24 to 48 hours following a single 2 mg IM injection. Benztropine binds extensively approximately 95%, with serum proteins. Benztropine crosses the blood-brain barrier.

### **INDICATIONS AND CLINICAL USE**

VPI-Benzotropine is recommended for all etiologic groups of Parkinsonism - arteriosclerotic, postencephalitic, idiopathic and drug-induced.

It can be effective at any stage of the disease, even when a patient has become bedridden. Often it is helpful in patients who have become unresponsive to other agents.

Though parkinsonism is chronic and usually progressive, its symptoms often can be controlled by suitable treatment. Therapy is directed toward control of disturbing symptoms to permit maximum integration of function and minimum discomfort.

In non-drug-induced parkinsonism, partial control of symptoms is the usual therapeutic accomplishment.

VPI-Benztropine is a powerful anticholinergic agent, mainly effective in relieving tremor and rigidity. Many other troublesome signs and symptoms, including sialorrhea, drooling, mask-like facies, oculogyric crises, speech and writing difficulties, dysphagia, gait disturbances, and pain and insomnia due to cramps and muscle spasm are also ameliorated.

Extensive muscle rigidity and spasm, often more disturbing than tremor may be alleviated.

Improvement in muscle function relieves many stigmata of parkinsonism. During therapy with VPI-Benztropine, the characteristic frozen facies, gait, and posture return toward normal; speech becomes freer; and sustained rigidity; discomfort, and restlessness during sleep usually are relieved.

Physiotherapy can be applied more easily and may be more effective.

### **Drug-Induced Parkinsonism**

VPI-Benztropine relieves manifestations of Parkinsonism that may appear during treatment with phenothiazine derivatives and reserpine. Usually it is helpful in combatting tremulousness; restlessness; feelings of tension; ptialism; urinary frequency, "lockjaw"; and acute dystonic reactions such as torticollis, oculogyric crises, and dysphagia.

### **CONTRAINDICATIONS**

Because of its atropine-like side effects, this drug is contraindicated in children under three years of age, and should be used with caution in older children.

The use of the drug is contraindicated in the presence of glaucoma (see PRECAUTIONS).

VPI-Benztropine is contraindicated in patients who are hypersensitive to any component of this product.

### **WARNINGS**

**Pregnancy:** The safe use of this drug in/pregnancy has not been established.

**Occupational Hazards:** Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.

## **PRECAUTIONS**

### **General**

Since VPI-Benzotropine has cumulative action, continued supervision is advisable.

Patients with a tendency to tachycardia, and patients with prostatic hypertrophy, should be closely observed during treatment. Dysuria may occur, but rarely becomes a problem.

The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it should not be used in narrow-angle glaucoma.

In large doses, the drug may cause complaints of weakness and inability to move particular muscle groups. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.

Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal symptoms due to central nervous system drugs, such as phenothiazines, and reserpine in patients with a mental disorder, occasionally there may be intensification of mental disorders. Although benztropine mesylate need not be discontinued when this occurs, the psychotogenic potential of antiparkinsonian drugs should be considered when planning the management of patients with mental disorders. Also, when using benztropine mesylate in these patients they should be kept under careful observation especially at the beginning of treatment or if dosage is increased. In such cases, at times, increased doses of antiparkinsonian drugs can precipitate a toxic psychosis.

Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs have been discontinued.

Antiparkinsonism agents usually do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate or unmask such symptoms. VPI-Benzotropine is not recommended in tardive dyskinesia.

Benztropine mesylate contains structural features of atropine and may produce anhidrosis. For this reason, it should be given with caution during hot weather, especially when given concomitantly with other atropine like drugs to the chronically ill, the alcoholic, those who have central nervous system disease and those who do manual labor in a hot environment.

Anhidrosis may be anticipated to occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.

### **Use in Obstetrics**

See **WARNINGS**.

### **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VPI-Benztropine is administered to a nursing mother.

### **Use in Children**

See **CONTRAINDICATIONS**.

### **Drug Interactions**

When VPI-Benztropine is given concomitantly with phenothiazines, haloperidol or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints fever or heat intolerance promptly. Paralytic ileus, sometimes fatal, has occurred in patients taking anticholinergic-type ant/parkinsonism drugs, including VPI-Benztropine, in combination with phenothiazines and/or tricyclic antidepressants.

## **ADVERSE REACTIONS**

Adverse reactions most of which are anticholinergic or antihistaminic in nature are listed below by body system in order of decreasing severity:

### **Cardiovascular**

Tachycardia.

### **Digestive**

Constipation, dry mouth, nausea, vomiting.

Adjustment of dosage or time of administration sometimes helps to control these reactions. If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.

Nausea unaccompanied by vomiting usually can be disregarded. Slight reduction in dosage may control the nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.

### **Nervous System**

Toxic psychosis including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.

### **Special Senses**

Blurred vision, dilated pupils.

### **Urogenital**

Urinary retention, dysuria.

### **Metabolic/Immune and Skin**

Occasionally, an allergic reaction, e.g. skin rash, develops. Sometimes this can be controlled by reducing dosage, but occasionally benztrapine mesylate has to be discontinued.

### **Other**

Heart stroke, hyperthermia, and fever.

## **SYMPTOMS AND TREATMENT OF OVERDOSAGE**

Manifestations: May be any of those seen in atropine poisoning or antihistamine overdose: CNS depression, preceded or followed by stimulation; confusion; nervousness; listlessness; intensification of mental symptoms or toxic psychosis in patients with mental illness being treated with phenothiazine derivatives or reserpine; hallucinations [especially visual]; dizziness; muscle weakness; ataxia; dry mouth; mydriasis; blurred vision; palpitations; nausea; vomiting; dysuria; numbness of fingers; dysphagia; allergic reactions, e. g., skin rash; headache; hot, dry, flushed skin; delirium; coma; shock; convulsions; respiratory arrest; anhidrosis; hyperthermia; glaucoma; constipation.

**Treatment:** Physostigmine salicylate, 1 to 2 mg, s.c. or i.v., reportedly will reverse symptoms of anticholinergic intoxication [Duvoisin, R.C., Katz R., J. Amer. Med. Ass. 1968, 206:1963-1965]. A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage [contraindicated in precoma, convulsive, or psychotic states]. Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression [avoid convulsant stimulants such as picrotoxin, pentylentetrazol, or bemegride]; artificial respiration for severe respiratory depression; a local miotic for mydriasis

and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.

## **DOSAGE AND ADMINISTRATION**

VPI-Benztropine is available as an injection for intravenous and intramuscular use.

The injection is especially useful for psychotic patients with acute, dystonic reactions or other reactions that make oral medication difficult or impossible. It is recommended also when a more rapid response is desired than can be obtained with the tablets.

Since there is no significant difference in onset of effect after intravenous and intramuscular injection, usually there is no need to give VPI-Benztropine intravenously. It is quickly effective after either route, with improvement sometimes noticeable a few minutes after injection. In emergency situations, when the condition of the patient is alarming, 1 to 2 ml of VPI-Benztropine normally will provide quick relief. If the signs of parkinsonism begin to return, the dose can be repeated.

Because VPI-Benztropine has cumulative action, therapy should be initiated with a low dose, which is increased gradually at five or six day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg to a maximum of 6 mg, or until optimal results are obtained without excessive side effects.

### **Arteriosclerotic, Idiopathic and Postencephalitic Parkinsonism**

The usual daily dosage of VPI-Benztropine is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.

As with any agent used in parkinsonism, dosage must be individualized according to age and weight and the type of parkinsonism being treated. Generally, older patients, thin patients, and patients with arteriosclerotic Parkinsonism cannot tolerate large dose of VPI-Benztropine. However, most patients with postencephalic parkinsonism require fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.

In arteriosclerotic and idiopathic parkinsonism, therapy may be initiated with a single daily dose of 0.5 to 1 mg at bedtime. In some patients, this will be adequate; in others, 4 to 6 mg a day may be required.

In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more dose. In highly, sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary.

Some patients experience greatest relief by taking the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.

The long duration of action of VPI-Benztropine makes it particularly suitable for bedtime medication when its effects may last throughout the night. With VPI-Benztropine patients are better able to turn in bed during the night and to rise in the morning.

When VPI-Benztropine is started, do not terminate therapy with other antiparkinsonian agents abruptly; rather, reduce or discontinue them gradually. Many patients obtain greatest relief with a combination of VPI-Benztropine and other drugs.

VPI-Benztropine may be administered concomitantly with levodopa in which case the dose of each may need to be adjusted. However, if VPI-Benztropine is continued when levodopa/carbidopa (in combination) is introduced, the dosage of VPI-Benztropine may need to be adjusted.

### **Drug-Induced Parkinsonism**

When treating extrapyramidal disorders due to central nervous system drugs such as phenothiazine derivatives or reserpine, the recommended dosage is 1 to 4 mg once or twice a day orally or parenterally. Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much.

In acute dystonic reactions, 1 to 2 mg of VPI-Benztropine intravenously quickly relieves the condition. After that, 1 to 2 mg given orally twice a day usually prevents recurrence.

Extrapyramidal disorders that develop soon after initiation of treatment with phenothiazines or reserpine are likely to be transient. One to 2 mg of benztropine mesylate orally, two or three times a day usually provides relief within one or two days. After one or two weeks of administration, VPI-Benztropine should be withdrawn to determine the continued need for it. If Parkinsonism recurs, VPI-Benztropine can be reinstated.

Certain extrapyramidal disorders which develop slowly, such as tardive dyskinesia, usually do not respond to VPI-Benztropine.

Patients must be closely observed for severe reaction and VPI-Benztropine discontinued temporarily if they appear. (See **PRECAUTIONS** and, **ADVERSE REACTIONS**)

VPI-Benztropine should not be used beyond the period necessary to counteract the extrapyramidal manifestations. Although medication with the drug causing Parkinsonism can frequently be continued without change of dosage when adjunct therapy with VPI-Benztropine is used, a reduction in dosage of the psychotropic drug might be indicated.

**SUPPLIED**

Each ml of sterile clear colorless solution contains: 1 mg of Benztropine mesylate and 9 mg of Sodium chloride in water for injection. Hydrochloric acid and/or Sodium hydroxide may have been added to adjust the pH. Vials of 2 ml, boxes of 10.

**STORAGE**

Store between 15 and 30°C. Protect from freezing.

**SINGLE USE VIAL**

Discard unused portion

Date of Revision: March 21, 2019